Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis

NCT00042068 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00042068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00042068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
July 31, 2003
Enrollment
1,000
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid